A Retrospective Study on Personalized Dosing Strategy of Patients Treated by Carbapenems: 2018-2021

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients may benefit from the personalized carbapenem dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review and analyze the clinical outcomes of patients with different dosing strategy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?

NCT01995760

Methicillin-resistant Staphylococcus Aureus Septicemia

COMPLETED

Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

NCT01401010

Febrile Neutropenia

COMPLETED PHASE4

Real-world Daptomycin Use in Chinese ICUs

NCT03588637

Daptomycin Real-world Study Intensive Care Unit

COMPLETED

Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model

NCT06161870

Severe Infection

RECRUITING PHASE4

Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

NCT02482961

Acinetobacter Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rational use of carbapenem is closely associated with the clinical outcome of patients with infections. Serum concentration of carbapenem varies from different populations. The objective of this study is to describe the clinical outcome of patients with infection treated by carbapenem in China, regarding diagnosis, treatment and follow-up. It is a single-center, retrospective, descriptive study. Inclusion criteria are an age ≥ 18, diagnosed as bacteria infection and serum concentration must be determined during therapy. Data concerning clinical presentation, biological samples, treatment and follow-up will be assessed. A descriptive analysis will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CAR-R

Patients with impaired renal function (eGFR \< 60ml/min/1.73m2) treated by carbapenem

No interventions assigned to this group

CAR-L

Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by carbapenem

No interventions assigned to this group

CAR-LR

Patients with co-morbidity of both liver cirrhosis or impaired liver function (Child-Pugh grade B or C) and impaired renal function (eGFR \< 60ml/min/1.73m2) treated by carbapenem

No interventions assigned to this group

CAR-N

Patients with normal liver function or renal function treated by carbapenem

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age over 18 years Chinese patient: male or female Diagnosed as bacterial infection Treated by carbapenem Serum concentration determined during therapy

Exclusion Criteria

Duration of carbapenem treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of carbapenem

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No